Should Posterior Reversible Encephalopathy Syndrome Be Mainly Considered an Epileptic Disorder? Results of a Sequential Neurophysiological Study in a Pediatric Cohort

Abstract

Despite a wide number of studies trying to define clinical, physiopathological, and neuroradiological features of posterior reversible encephalopathy syndrome (PRES), the true nature of symptoms is still not fully understood. We studied a standard cohort of 24 pediatric patients, affected by hemato-oncological diseases, with a neuroradiological diagnosis consistent with PRES identified from 2006 to 2013. Ten of them developed PRES after hematopoietic stem cell transplantation. We analyzed the sequence of clinical, radiological, and electrophysiological data. In all the patients who were recorded at the onset of the first symptoms, electroencephalograms showed focal nonconvulsive seizures or status epilepticus (SE). We found a sensitivity of 100% for electroencephalogram (EEG) with a good correlation between clinical signs and the localization of seizures, whereas computed tomography scans showed a sensitivity of 50% only. Following prompt treatment, intensive care unit admission rate was only 8%. PRES is a multifactorial neurologic event with focal nonconvulsive seizures or SE as the main feature in pediatric patients. Clinical manifestations are epileptic in nature, and prompt EEG recording is useful for diagnosis and supports an earlier treatment, potentially preventing the appearance of complications such as generalized seizures or refractory SE.

Keywords

posterior reversible encephalopathy syndrome - seizures - leukemia - hematopoietic stem cell transplantation

• References

• 1 Hinchey J, Chaves C, Appignani B , et al. A reversible posterior leukoencephalopathy syndrome. N Engl J Med 1996; 334 (08) 494-500
• 2 Fugate JE, Rabinstein AA. Posterior reversible encephalopathy syndrome: clinical and radiological manifestations, pathophysiology, and outstanding questions. Lancet Neurol 2015; 14 (09) 914-925
• 3 Lucchini G, Grioni D, Colombini A , et al. Encephalopathy syndrome in children with hemato-oncological disorders is not always posterior and reversible. Pediatr Blood Cancer 2008; 51 (05) 629-633
• 4 Grioni D, Rovelli A, Pavan F, Prunotto G. The diagnosis of posterior reversible encephalopathy syndrome. Lancet Neurol 2015; 14 (11) 1073-1074
• 5 Pession A, Masetti R, Rizzari C , et al; AIEOP AML Study Group. Results of the AIEOP AML 2002/01 multicenter prospective trial for the treatment of children with acute myeloid leukemia. Blood 2013; 122 (02) 170-178
• 6 Conter V, Valsecchi MG, Parasole R , et al. Childhood high-risk acute lymphoblastic leukemia in first remission: results after chemotherapy or transplant from the AIEOP ALL 2000 study. Blood 2014; 123 (10) 1470-1478
• 7 Barone A, Lucarelli A, Onofrillo D , et al; Marrow Failure Study Group of the Pediatric Haemato-Oncology Italian Association; Guidelines from the Marrow Failure Study Group of the Pediatric Haemato-Oncology Italian Association (AIEOP). Diagnosis and management of acquired aplastic anemia in childhood. Blood Cells Mol Dis 2015; 55 (01) 40-47
• 8 Bakshi R, Bates VE, Mechtler LL, Kinkel PR, Kinkel WR. Occipital lobe seizures as the major clinical manifestation of reversible posterior leukoencephalopathy syndrome: magnetic resonance imaging findings. Epilepsia 1998; 39 (03) 295-299
• 9 Wennberg RA. Clinical and MRI evidence that occipital lobe seizures can be the major manifestation of the reversible posterior leukoencephalopathy syndrome (RPLS). Epilepsia 1998; 39 (12) 1381-1383
• 10 Kastrup O, Gerwig M, Frings M, Diener HC. Posterior reversible encephalopathy syndrome (PRES): electroencephalographic findings and seizure patterns. J Neurol 2012; 259 (07) 1383-1389
• 11 Kozak OS, Wijdicks EF, Manno EM, Miley JT, Rabinstein AA. Status epilepticus as initial manifestation of posterior reversible encephalopathy syndrome. Neurology 2007; 69 (09) 894-897
• 12 Sha Z, Moran BP, McKinney IV AM, Henry TR. Seizure outcomes of posterior reversible encephalopathy syndrome and correlations with electroencephalographic changes. Epilepsy Behav 2015; 48: 70-74
• 13 Siebert E, Spors B, Bohner G, Endres M, Liman TG. Posterior reversible encephalopathy syndrome in children: radiological and clinical findings - a retrospective analysis of a German tertiary care center. Eur J Paediatr Neurol 2013; 17 (02) 169-175
• 14 Striano P, Striano S, Tortora F , et al. Clinical spectrum and critical care management of Posterior Reversible Encephalopathy Syndrome (PRES). Med Sci Monit 2005; 11 (11) CR549-CR553
• 15 Li Y, Gor D, Walicki D , et al. Spectrum and potential pathogenesis of reversible posterior leukoencephalopathy syndrome. J Stroke Cerebrovasc Dis 2012; 21 (08) 873-882
• 16 Datar S, Singh T, Rabinstein AA, Fugate JE, Hocker S. Long-term risk of seizures and epilepsy in patients with posterior reversible encephalopathy syndrome. Epilepsia 2015; 56 (04) 564-568
• 17 Cordelli DM, Masetti R, Bernardi B , et al. Status epilepticus as a main manifestation of posterior reversible encephalopathy syndrome after pediatric hematopoietic stem cell transplantation. Pediatr Blood Cancer 2012; 58 (05) 785-790
• 18 Schmiegelow K, Attarbaschi A, Barzilai S , et al; Ponte di Legno toxicity working group. Consensus definitions of 14 severe acute toxic effects for childhood lymphoblastic leukaemia treatment: a Delphi consensus. Lancet Oncol 2016; 17 (06) e231-e239